Cargando…

Real world data on IO-based therapy for metastatic renal cell carcinoma

PURPOSE: Immune-based (IO)-combinations are the backbone in the systemic therapy of metastatic renal cell carcinoma (mRCC). Despite phase III clinical trial data, real world data are of special importance to reflect clinical practice. METHODS: This retrospective study included 201 mRCC patients rece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stühler, Viktoria, Herrmann, Lisa, Rausch, Steffen, Stenzl, Arnulf, Bedke, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314860/ https://www.ncbi.nlm.nih.gov/pubmed/35907009 http://dx.doi.org/10.1007/s00432-022-04173-0

Ejemplares similares

Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab
por: Stühler, Viktoria, et al.
Publicado: (2022)

Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies
por: Stühler, Viktoria, et al.
Publicado: (2022)

The prognostic value of fat invasion and tumor expansion in the hilar veins in pT3a renal cell carcinoma
por: Stühler, Viktoria, et al.
Publicado: (2021)

Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases
por: Maas, Moritz, et al.
Publicado: (2023)

Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors – assessment of intra-tumour heterogeneity
por: Stühler, Viktoria, et al.
Publicado: (2016)

MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma
por: Fisel, Pascale, et al.
Publicado: (2015)

Characterization of Genetic Heterogeneity in Recurrent Metastases of Renal Cell Carcinoma
por: Sauter-Meyerhoff, Carolin, et al.
Publicado: (2021)

Nicotinamide‐N‐methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma
por: Reustle, Anna, et al.
Publicado: (2022)

Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma
por: Büttner, Florian, et al.
Publicado: (2018)

A Rare Case of Synchronous Renal Cell Carcinoma of the Bladder Presenting With Gross Hematuria
por: Kruck, Stephan, et al.
Publicado: (2013)

Circulating tumor cells and their role in prostate cancer
por: Maas, Moritz, et al.
Publicado: (2019)

Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma
por: Bedke, Jens, et al.
Publicado: (2015)

Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy
por: Bedke, Jens, et al.
Publicado: (2013)

Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer
por: Hegemann, Miriam, et al.
Publicado: (2019)

Versatility and clinical effectiveness of a synthetic sealing hemostatic patch as alternative to parenchyma suturing in laparoscopic partial nephrectomy
por: Erne, Eva, et al.
Publicado: (2021)

Impact of an Altered Wnt1/β-Catenin Expression on Clinicopathology and Prognosis in Clear Cell Renal Cell Carcinoma
por: Kruck, Stephan, et al.
Publicado: (2013)

Systemic therapy in metastatic renal cell carcinoma
por: Bedke, Jens, et al.
Publicado: (2016)

Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?
por: Bier, Simone, et al.
Publicado: (2018)

A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy
por: Büttner, Florian A., et al.
Publicado: (2022)

Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy
por: Thaiss, Wolfgang M., et al.
Publicado: (2022)

Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases
por: Aufderklamm, Stefan, et al.
Publicado: (2018)

Severe paraneoplastic hypereosinophilia in metastatic renal cell carcinoma
por: Todenhöfer, Tilman, et al.
Publicado: (2012)

Is a single portal venous phase in contrast-enhanced CT sufficient to detect metastases or recurrence in clear cell renal cell carcinoma? – a single-center retrospective study
por: Hagen, Florian, et al.
Publicado: (2022)

IoT solutions in Microsoft's Azure IoT suite: data acquisition and analysis in the real world
por: Klein, Scott
Publicado: (2017)

Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
por: Reustle, Anna, et al.
Publicado: (2020)

Sunitinib in Metastatic Renal Cell Carcinoma: A Systematic Review of UK Real World Data
por: Argyropulo-Palmer, Miriam, et al.
Publicado: (2015)

Real world treatment sequences and outcomes for metastatic renal cell carcinoma
por: Lai, Gu-Shun, et al.
Publicado: (2023)

Thioredoxin 1 (Trx1) is associated with poor prognosis in clear cell renal cell carcinoma (ccRCC): an example for the crucial role of redox signaling in ccRCC
por: Ribback, Silvia, et al.
Publicado: (2021)

A Peritoneal Purse-String Suture Prevents Symptomatic Lymphoceles in Retzius-Sparing Robot-Assisted Radical Prostatectomy
por: Harland, Niklas, et al.
Publicado: (2023)

Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes
por: Winter, Stefan, et al.
Publicado: (2016)

Managing metastatic renal cell carcinoma-challenges, pitfalls, and outcomes in the real world
por: Kumar, Karnam Ashok, et al.
Publicado: (2016)

Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment
por: Meerveld-Eggink, Aafke, et al.
Publicado: (2022)

MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients
por: Lukamowicz-Rajska, Magdalena, et al.
Publicado: (2016)

Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands
por: van Laar, S.A., et al.
Publicado: (2022)

p53 is functionally inhibited in clear cell renal cell carcinoma (ccRCC): a mechanistic and correlative investigation into genetic and molecular characteristics
por: Diesing, Karoline, et al.
Publicado: (2021)

Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data
por: Moran, Michael, et al.
Publicado: (2019)

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
por: Santoni, Matteo, et al.
Publicado: (2019)

Systemic treatment of advanced/metastatic renal cell carcinoma in the context of SARS-CoV-2 pandemic: recommendations from the interdisciplinary working group for renal tumors (IAG-N)
por: Ivanyi, Philipp, et al.
Publicado: (2020)

Utility of pT3 substaging in lymph node-negative urothelial carcinoma of the bladder: do pathologic parameters add to prognostic sub-stratification?
por: Maas, Moritz, et al.
Publicado: (2021)

Minimal-invasive management of urological complications after kidney transplantation
por: Deininger, Susanne, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6pc271vajagmiba76oglbe3bco